Text size:

BEOVU

12 May, 2022

Home / Resources / Current Research Trials / BEOVU

Brolucizumab Treatment For Pigment Epithelial Detachment In Treatment-Resistant Neovascular Age Related Macular Degeneration

Study Type :	Observational
Estimated Enrollment :	600 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	OBservationaL stUdy to Evaluate Fluid reSolution and Effectiveness in Patients Receiving Beovu (Brolucizumab) Under KeY Treatment Schemes in Neovascular Age-related Macular Degeneration
Actual Study Start Date :	November 5, 2020
Estimated Primary Completion Date :	November 7, 2024
Estimated Study Completion Date :	November 7, 2024

Related Publications

Our Affiliates

Procedures

Team

Appointments

Resource Centre

Patient Information

Contact & Parking

Home

We acknowledge the Traditional Owners and Custodians of the land, the Eora Nation, on which we work and pay our respects to their Elders, both past and present.

Everyone deserves the best care. We foster an inclusive culture by embracing and valuing diversity and equality for our work colleagues and patients. This philosophy extends to everyone we interact with and the communities we serve. You are valued, regardless of race, colour, sexual orientation, gender identity, religion, national origin, ancestry, physical abilities and age.